Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer

J. N. Ingle, D. L. Ahmann, S. J. Green, J. H. Edmonson, E. T. Creagan, R. G. Hahn, J. Rubin

Research output: Contribution to journalArticle

66 Scopus citations

Abstract

Fifty-five women with progressive metastatic breast cancer who were paramenopausal (1 to <5 years since last menstrual period) or castrated were randomized to receive either megestrol acetate (150 mg/m2 daily in three divided doses) or tamoxifen (10 mg twice daily). The regression rate (complete plus partial) was higher for tamoxifen (26%) than for megestrol acetate (14%), but not significantly so. Analysis of time to treatment failure showed no significant difference (medians: megestrol acetate, 65 days; tamoxifen, 58 days). There was a survival advantage associated with megestrol acetate (P = 0.02 after adjustment for stratification factors) that is difficult to interpret given the results of analysis of regression and time to treatment failure for the two agents.

Original languageEnglish (US)
Pages (from-to)155-160
Number of pages6
JournalUnknown Journal
Volume5
Issue number2
DOIs
StatePublished - Jan 1 1982

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Ingle, J. N., Ahmann, D. L., Green, S. J., Edmonson, J. H., Creagan, E. T., Hahn, R. G., & Rubin, J. (1982). Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer. Unknown Journal, 5(2), 155-160. https://doi.org/10.1097/00000421-198204000-00062